LAW OFFICES FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P. 1300 I Street, NW

Washington, DC 20005

Telephone (202) 408-4000

Facsimile (202) 408-4400

FACSIMILE TRANSMITTAL

TO

Examiner S. Kaushal

Name: Firm:

U.S. Patent and Trademark Office

Fax No.:

703-746-3124

Phone No.: 703-305-6838

Subject:

USSN 09/244,130

Our Ref.:

03495.0111-10000

FROM

Name: Salvatore J. Arrigo

Phone No.: 202-408-4160

Fax # Verified by: K. Smith/MD820

Pages (incl. this): 🍎

Date:

February 5, 2003

Confirmation Copy to Follow: ___ Yes ____No

Certification of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Dated: February 5, 2003

Examiner: S. Kaushal - Fax No.: (703) 746-3124

If there is a problem with this transmission, notify fax room at (202) 408-4174 or the sender at the number

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify the sender immediately by telephone (collect), and return the original message by first-

Attorney Docket No. 3495.0111-10 Customer No. 22,852

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Group Art Unit: 1636 Bernard DUJON et al. Examiner: KAUSHAL, S.

Filed: February 4, 1999

For: NUCLEOTIDE SEQUENCE ENCODING

THE ENZYME I-SCEI AND THE USES THEREOF

Commissioner for Patents Washington, D.C. 20231

Serial No.: 09/244,130

Sir:

SUPPLEMENTAL AMENDMENT

Applicants filed an RCE on November 26, 2002. Applicants submit the following supplemental amendments and remarks. Please amend this application as follows: IN THE CLAIMS:

Please cancel claims 53-86.

Please add the following new claims:

-- 94. (NEW) A transgenic mouse comprising a recombinant cell, wherein said cell comprises a nucleotide sequence, wherein said nucleotide sequence comprises a Group I intron encoded endonuclease recognition site,

wherein the site is selected from the group consisting of an I-SceIV site, an I-CsmI site, I-PanI site, I-SceII site, an I-CeuI site, an I-PpoI site, an I-SceIII site, an I-CreI site, an I-TevI site, an I-TevII site, an I-TevIII site, and an I-SceI site.

95. (NEW) The transgenic mouse of claim 94, wherein the site is an I-SceIV site.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNERLL

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com